Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Drug Profile

Varicella zoster virus vaccine - Sinovac (Dalian) Vaccine Technology

Alternative Names: Live attenuated varicella vaccine - Sinovac Biotech/Dalian Vaccine Technology; Varicella zoster vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Sinovac (Dalian) Vaccine Technology
  • Developer Sinovac (Dalian) Vaccine Technology
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Varicella zoster virus infections

Most Recent Events

  • 01 Dec 2017 Sinovac (Dalian) Vaccine Technology submits production license application to China FDA for Varicella zoster virus vaccine
  • 22 Nov 2017 Sinovac (Dalian) Vaccine Technology announces intention to file the production license application with the CFDA in late 2017
  • 25 Sep 2017 Preliminary efficacy data from a phase III trial in Varicella zoster virus infections released by Sinovac Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top